Iovance Biotherapeutics Inc IOVA Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Sep 18, 2023 (filed on Sep 19, 2023)

Insider Name:

Mcpeak Merrill A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

10,000

Price:

$5.56
Sep 15, 2023 (filed on Sep 15, 2023)

Insider Name:

Rothbaum Wayne P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000,000

Price:

$5.30
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Vogt Frederick G

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-20,834

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Vogt Frederick G

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-8,851

Price:

$7.76
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Vogt Frederick G

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

20,834

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Graf Finckenstein Friedrich

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,813

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Graf Finckenstein Friedrich

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,395

Price:

$7.76
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Graf Finckenstein Friedrich

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,813

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Bilinsky Igor

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,813

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Bilinsky Igor

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,395

Price:

$7.76

Filings by filing date

Sep 18, 2023 (filed on Sep 19, 2023)

Insider Name:

Mcpeak Merrill A

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

10,000

Price:

$5.56
Sep 15, 2023 (filed on Sep 15, 2023)

Insider Name:

Rothbaum Wayne P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000,000

Price:

$5.30
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Vogt Frederick G

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-20,834

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Vogt Frederick G

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-8,851

Price:

$7.76
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Vogt Frederick G

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

20,834

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Graf Finckenstein Friedrich

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,813

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Graf Finckenstein Friedrich

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,395

Price:

$7.76
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Graf Finckenstein Friedrich

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,813

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Bilinsky Igor

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,813

Price:

--
Jul 14, 2023 (filed on Jul 17, 2023)

Insider Name:

Bilinsky Igor

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,395

Price:

$7.76

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	825 INDUSTRIAL ROAD, 4TH FLOOR SAN CARLOS CA 94070
Tel:	N/A
Website:	https://www.iovance.com
IR:	See website

Key People

Frederick G. Vogt Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary	Jean-Marc Bellemin Chief Financial Officer	Igor P. Bilinsky Chief Operating Officer
Friedrich Graf Finckenstein Chief Medical Officer

Business Overview

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company, which commercializes autologous T-cell therapy to address solid tumor cancer. It develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. It has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The Company is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201.

Financial Overview

For the six months ended 30 June 2023, Iovance Biotherapeutics Inc revenues increased from $0K to $238K. Net loss increased 12% to $213.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects focused on developing and commercializing segment loss increase of 20% to $110.1M.

Employees:	503 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$882.45M as of Jun 30, 2023
Annual revenue (TTM):	$0.24M as of Jun 30, 2023
EBITDA (TTM):	-$415.44M as of Jun 30, 2023
Net annual income (TTM):	-$418.84M as of Jun 30, 2023
Free cash flow (TTM):	-$354.68M as of Jun 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	247,358,979 as of Jul 13, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization